Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 949 for your search:
Start Over
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 80 and under
Trial IDs: 2015-0313, NCI-2016-00584, NCT02727803
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA180-399, NCI-2012-02781, 2011-006181-41, NCT01593254
Abatacept, Cyclosprine, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease in Patients with High-Risk Leukemia Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 and over
Trial IDs: 2692.00, NCI-2016-00220, PBMTC PROTOCOL GVH 1201, NCT01743131
Fludarabine Phosphate, Clofarabine, and Busulfan with Vorinostat in Treating Patients with Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and under
Trial IDs: 2012-0999, NCI-2014-01982, NCT02083250
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: DS3032-A-U102, NCI-2015-00023, NCT02319369
Leuprolide Acetate in Improving Immune Recovery and 18F FLT PET/CT in Predicting Immune Recovery after Donor Bone Marrow Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 9 to 55
Trial IDs: 11-C-0136, NCI-2013-01485, 110136, P10780, NCT01338987
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: PT-001, NCI-2016-00907, NCT02743351
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-23, NCI-2016-01196, NCT02711852
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 21
Trial IDs: CCTL019B2205J, NCI-2016-00815, 14BT022, NCT02228096
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-103HEME, NCI-2015-00445, BBI608-103HEM, NCT02352558
T-cell Depleted Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 14-228, NCI-2015-00179, NCT02350777
Intra-osseous Donor Umbilical Cord Blood and Mesenchymal Stromal Cell Co-transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 75
Trial IDs: CASE1Z14, NCI-2014-01316, 10-14-33C, NCT02181478
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Collection and Analysis of Stored Human Samples, Specimens, or Data from Patients on Terminated Protocols
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: 08-C-N013, NCI-2015-01186, 04-C-0142, 08CN103, P07268, NCI-08-C-N013, NCT00904514
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, KPT330, NCT02091245
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months and over
Trial IDs: CCCWFU# 99213, NCI-2013-00965, NCT01869803
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00010262, NCI-2014-00633, 10262, NCT02092324
Start Over